Learn More -

After Clearing Valeant Litigation, Jaguar and Napo Pharmaceuticals Reunite

By: , The Street

Napo Pharmaceuticals has made good on its promise to take Jaguar Animal Health (JAGX) back after spinning the company off in 2013.

Jaguar shares spiked early on the news Friday from a $1 opening price to as high as $1.25 wihtin a half hour of the opening bell. The shares slid throughout the day and returned to to their opening level by market’s close.

The two announced a reverse merger Friday in which Jaguar’s stockholders and option and warrant holders will end up with approximately 25% of the total company, while Napo, which already owns 19% of Jaguar’s shares, will end up with the remaining pieces of the company.

As a part of the deal, Napo has entered into a settlement to pay off one of its secured creditors, paying $8 million in cash and certain Jaguar voting and nonvoting shares.The newly formed company will trade under the JAGX ticker, and will operate under the name Jaguar Health Inc.

“It was a smooth, collaborative process,” CEO Lisa Conte said by phone Friday. “There was just a lot of work to do. There were 11 parties to coordinate with eight different lawyers.”

The deal was previously announced back in October, when the two entered into a letter of intent for a reverse merger.

Jaguar was spun out from Napo back in 2013, when Napo took the animal health company public to take advantage of the growing animal health market.

But the companies decided reintegration would be a smart move after Jaguar faced intense litigation with Salix Pharmaceuticals (SLXP) and then Valeant (VRX) . The litigation was over Napo’s crofelemer, which is in trials for indications including chemotherapy-induced diarrhea. Valeant acquired Salix’s licensing rights to the drug, known as Mytesi on the markets, which is how it became involved in the suit.

“There was litigation financed debt that needed to be restructured,” Conte said. She added that as a part of the settlement, Jaguar received the licensing rights to Mytesi back from Valeant.

When you settle, that’s technically considered a win,” Conte added. “We needed to restructure that debt to allow Napo to go forward.”

That five-year-long lawsuit came to an end last May, which is when the two started discussing plans for reintegration. Much of the staff worked for both companies already anyway, Conte told The Deal in October.

After the deal closed, the two likely would focus on reintegration before doing more deals. However, Conte noted that now that the litigation is behind Jaguar, the company can focus on forming partnerships with others for licensing and marketing deals.

According to Conte, Jaguar is in exclusive talks over rights to its horse diarrhea drug with a large animal health company. However, she was unable to reveal which company Jaguar is in talks with.

Reed Smith LLP and Stifel Nicolaus & Company Inc. are serving as Jaguar’s legal and financial advisers, respectively on the deal. Meanwhile, Napo engaged Boies Schiller Flexner as its legal adviser on the deal.

Source: https://www.thestreet.com/story/14068391/2/after-clearing-valeant-litigation-jaguar-and-napo-pharmaceuticals-reunite.html

My HIV Thank You™ Campaign Allows People Living with HIV to Acknowledge Someone Who Has Helped Them

HIV Advocates Provide Platform for People Living with HIV to Share Personal Experiences of Someone Who Has Positively Impacted Their Life

NEW YORK, NY – March 22, 2017 – Napo Pharmaceuticals Inc. (“Napo”), announced today the launch of My HIV Thank You™, a social media campaign they are sponsoring which provides a platform for people living with HIV/AIDS, to share their personal stories of how someone – a doctor or other healthcare provider, friend, family member or person who has passed on – has made a positive impact on their HIV journey. By sharing stories, in the form of audio or video, words or pictures, at HIVThankYou.com, participants have an opportunity to share a moment of gratitude and help make a difference for others affected by HIV. This program is the brainchild of HIV advocates who feel sharing positive experiences is an important part of living with HIV. Napo is the manufacturer of Mytesi, the only antidiarrheal studied in and FDA-approved for the relief of diarrhea in HIV+ patients.

“Living with HIV requires access to multiple resources, such as those provided by healthcare professionals and others living with HIV,” said Lisa Conte, CEO, Napo Pharmaceuticals. “Napo is sponsoring My HIV Thank You to advocate for the HIV community and their healthcare providers by offering a platform to highlight the inspirational moments of people living with HIV and AIDS, which has certainly inspired me.”

Napo has brought together some of the leading voices in the HIV community who conceived of the campaign based on their own experiences. Josh Robbins is an HIV/AIDS activist and the founder of imstilljosh.com and “HIV Video Minute.” Josh says,

“Since being diagnosed, I’ve read and heard encouragement from thousands of people on the same journey as me. My piece of advice is simple – start talking. And make that talk encouraging to others.”

Joining Josh in this effort is Maria Mejia, a powerful advocate for HIV education, treatment, testing and prevention. In her own words, Maria noted, “I am one of the faces of HIV. No more shame, no more stigma! We are just human beings that happen to have the condition of HIV. It’s that simple.”

To learn more about the My HIV Thank You visit HIVThankYou.com

About My HIV Thank You

My HIV Thank You™ is sponsored by Napo Pharmaceuticals, the maker of Mytesi (crofelemer), the only antidiarrheal studied in and FDA-approved for the relief of diarrhea in HIV+ patients.1 Designed to inspire and energize, My HIV Thank You™ calls for people living with or affected by HIV to share their positive personal stories with their healthcare providers or others who have helped them throughout their HIV journey.

About the Advisors

Josh Robbins is an HIV/AIDS activist, and publisher of the 2017 GLAAD Award nominated blog, imstilljosh.com. He hosts a digital news series across all social media platforms #HIVscoop. In 2015, he won the ADAP Advocacy Award for Social Media Campaign of the Year. He is the creator of two iOS apps: disclosur+ and Ask HIV, as well as the first HIV-related iMessage sticker pack. Recently, he signed on with the weekly podcast, POZ I AM Radio, offering an exclusive #HIVscoop to the program. His videos have garnered more than 1.4 Million minutes watched. Robbins currently resides in Nashville, Tennessee and owns a small health communications agency—the BRANDAGEMENT.

Maria Mejia has lived with HIV for over 27 years and is the co-author of her biography, “From a Warrior’s Passion and Pain.” Maria is a powerful activist for HIV education, treatment, testing and prevention, with a strong presence in traditional and social media. She is an active blogger and vlogger, motivational speaker and founder of a prominent international HIV/AIDS support group online. Maria is involved in several campaigns, including “Dab the AIDS Bear Project,” the US Center for Disease Control and Prevention’s “Let’s Stop HIV Together” program and the “The Stigma Project.” She also serves as a Global Ambassador for The Well Project. Maria lives with her wife, Lisa, in Miami, FL.

About Mytesi™

Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.

Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

More information and complete Prescribing Information are available at Mytesi.com.

About Napo Pharmaceuticals, Inc.

San Francisco-based Napo Pharmaceuticals, Inc., focuses on the development and commercialization of proprietary pharmaceuticals from rainforest resources for the global marketplace in collaboration with local partners. Recently, Napo and Jaguar Animal Health, Inc. (NASDAQ: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, foals, and high value horses, announced plans for a proposed merger of the two companies.

Media Contacts:
Kate Tumino
KCSA Strategic Communications

1Mytesi™ is an anti-diarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy.

Napo Pharmaceuticals Signs Agreement with Alamo Pharma Services to Launch National Sales Force for Mytesi

Napo Pharmaceuticals, Inc., a company focused on the development and commercialization of proprietary pharmaceuticals for the global marketplace from plants traditionally used in rainforest areas, announces today that it has signed an agreement with Alamo Pharma Services, Inc. for the establishment and management of a national sales team for Mytesi™ (formerly known as Fulyzaq). Mytesi™, launched by Napo in October 2016, is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.

Read More
Optimization WordPress Plugins & Solutions by W3 EDGE